TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 52,400 shares, a growth of 184.8% from the November 30th total of 18,400 shares. Approximately 7.5% of the shares of the stock are sold short. Based on an average daily volume of 59,000 shares, the short-interest ratio is currently 0.9 days.

TransCode Therapeutics Stock Down 5.7 %

RNAZ stock opened at $3.67 on Friday. The firm’s fifty day moving average is $308.26 and its 200 day moving average is $500.08. TransCode Therapeutics has a 52 week low of $3.21 and a 52 week high of $236.94.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price objective on TransCode Therapeutics from $3.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its stake in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.